MADRIGAL PHARMACEUTICALS INC (MDGL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MDGL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MDGL | Class III Director | 64 | ["Previously served as Chief Executive Officer of Agios Pharmaceuticals, Inc.","Served as Executive Chair of Dermavant Sciences, Inc.","Served in various leadership capacities at Celgene Corporation","Chief Financial Officer of Bunge Limited","Senior Vice President, Chief Financial Officer and Corporate Strategy at Alcon Laboratories, Inc.","Held a variety of senior leadership roles with international companies in Europe"] | ["Science and Technology","Nominating and Governance","Compensation"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| INCY | Independent Director | 64 | ["Chief Executive Officer of Agios Pharmaceuticals, Inc. from February 2019 until August 2022","Chair of the Agios Board of Directors since August 2022","Executive Chair of Dermavant Sciences from July 2017 to September 2018","Various roles at Celgene Corporation from September 2010 to June 2017","Chief Financial Officer of Bunge Limited from July 2007 to September 2010","Senior Vice President, Chief Financial Officer and Corporate Strategy at Alcon Laboratories, Inc.","Senior leadership roles with international companies in Europe including Swissair and Nestle","Significant executive leadership and corporate finance expertise"] | ["Audit and Finance","Nominating and Corporate Governance"] | 2026 |
| AGIO | Chief Executive Officer | 60 | [] | [] | 2022 |
Biography sourced from the proxy statement filing.
Previously served as Chief Executive Officer of Agios Pharmaceuticals, Inc. (Agios), a publicly traded biopharmaceutical company, from February 2019 until her retirement in August 2022. Served as Executive Chair of Dermavant Sciences, Inc., a biopharmaceutical company, from July 2017 to September 2018. Served in various leadership capacities at Celgene Corporation, a biopharmaceutical company, including Strategic Advisor to the Management Executive Committee from April 2017 to June 2017, President and Chief Operating Officer from March 2016 to March 2017, President, Hematology and Oncology from August 2014 to February 2016, Executive Vice President and Chief Financial Officer from February 2012 to July 2014 and Senior Vice President and Chief Financial Officer from September 2010 to February 2012. Chief Financial Officer of Bunge Limited, a global agribusiness and food company, from July 2007 to September 2010. Senior Vice President, Chief Financial Officer and Corporate Strategy at Alcon Laboratories, Inc. from 2006 to 2007 and prior to that, held the position of Senior Vice President and Chief Financial Officer. Held a variety of senior leadership roles with international companies in Europe, including Swiss International Air Lines AG and Nestle S.A. from 2002 to 2006. Dr. Fouse earned a B.A. and M.A. in Economics and a Ph.D. in Finance from The University of Texas at Arlington. Other Company Board Service Dr. Fouse serves on the board of directors of the following publicly traded companies: Incyte since November 2017 Agios since December 2017 Qualifications We believe that Dr. Fouse is qualified to serve on our Board due to her significant executive leadership, corporate finance, financial reporting and accounting expertise. Additionally, Dr. Fouse is able to provide diverse and valuable corporate governance, management, operational and strategic expertise to the Board through her experience as an executive officer and a public company board member.